Psychedelics are no longer confined to counterculture conversations or underground movements. A new national survey suggests they are quietly becoming part of everyday life for millions of Americans. According to recent research from the RAND Corporation, an estimated 10 million adults in the United States microdosed psychedelic substances in 2025. This growing trend highlights a shift in how people view and use psychedelics, not for intense hallucinations, but for subtle mental and emotional benefits.
Microdosing involves taking very small amounts of psychedelic drugs such as psilocybin, LSD, or MDMA without the intention of experiencing a full psychedelic “trip.” Instead, users report seeking improvements in mood, creativity, focus, and mental well being. The findings raise important questions about mental health, public policy, safety, and the future of psychedelic research in the United States.
Microdosing refers to the practice of consuming a dose of a psychedelic substance that is well below the threshold needed to cause noticeable alterations in perception or consciousness. These doses are typically taken on a schedule, such as every few days, rather than daily use.
People who microdose generally report that they can go about their normal routines, including work and social activities, without impairment. The goal is not intoxication, but subtle changes in emotional balance, creativity, or mental clarity.
Commonly microdosed substances include psilocybin mushrooms, LSD, and MDMA. Some individuals also report microdosing ketamine or certain mushroom species, although safety concerns vary widely depending on the substance.
To better understand how widespread psychedelic use has become, researchers from RAND conducted a large national survey in September 2025. The survey included 10,122 U.S. adults and asked about lifetime and recent use of 11 different psychedelic substances. Participants were also asked whether they used full doses or microdoses.
The results showed that microdosing is far from a niche practice. Approximately 10 million American adults reported microdosing at least one psychedelic substance in 2025. Among those who use psychedelics at all, microdosing was found to be a common and significant pattern of use.
Michelle Priest, a research project specialist at RAND and lead investigator of the study, noted that while public discussion around microdosing has grown, there was previously little data on how common the practice actually is. The findings suggest that for many psychedelic users, taking small doses plays a central role in their overall use.
Survey data and background research indicate that people microdose for a wide range of reasons. The most commonly reported motivations include managing symptoms of anxiety and depression, improving mood, boosting creativity, and enhancing focus or productivity.
Some users describe microdosing as a tool for emotional regulation, helping them feel more balanced and less reactive to stress. Others view it as a way to support creative work or problem solving without the disruption associated with full psychedelic experiences.
It is important to note that while many individuals report perceived benefits, scientific evidence on the effectiveness of microdosing is still limited. Some studies suggest placebo effects may play a role, while others point to potential neurological or psychological mechanisms that warrant further investigation.
The RAND survey also revealed which psychedelic substances are most commonly used by American adults, regardless of dose size.
Psilocybin mushrooms ranked first, with an estimated 11 million adults reporting use. MDMA followed with approximately 4.7 million users, while Amanita muscaria mushrooms were reported by about 3.5 million adults. Ketamine use was estimated at 3.3 million adults, and LSD at around 3 million.
Beau Kilmer, co director of the RAND Drug Policy Research Center, said he was not surprised to see psilocybin at the top of the list, given its growing visibility in both research and public discourse. However, he noted surprise at the high ranking of Amanita muscaria, a mushroom known for both psychoactive effects and potential toxicity.
Amanita muscaria, also known as fly agaric, is a mushroom with a long history in folklore and traditional practices. While it can produce feelings of euphoria and altered perception, it is not considered a classic psychedelic like psilocybin.
Medical experts warn that Amanita muscaria can be dangerous. According to the American College of Emergency Physicians, ingestion may cause nausea, vomiting, loss of muscle coordination, confusion, and in severe cases, seizures. The popularity of this mushroom raises concerns about public awareness and safety.
Even substances often perceived as safer, such as psilocybin or LSD, carry risks. These include psychological distress, interactions with medications, and the possibility of exacerbating underlying mental health conditions. Because psychedelics remain illegal at the federal level, there is also significant variability in quality, dosage accuracy, and contamination in unregulated products.
Despite legal restrictions, scientific interest in psychedelics has grown rapidly in recent years. Organizations such as the American Psychological Association have highlighted ongoing research into the potential use of psychedelics for treating mood disorders, post traumatic stress disorder, and substance use disorders.
Clinical trials have explored the use of psilocybin assisted therapy for depression and end of life anxiety, while MDMA assisted therapy has shown promise for PTSD in controlled settings. Ketamine, which has legal medical uses, is already being prescribed in some cases for treatment resistant depression.
However, these therapeutic models differ significantly from microdosing. Clinical treatments involve carefully controlled doses, professional supervision, and structured psychotherapy. Microdosing, by contrast, is typically self directed and occurs outside medical settings.
At the federal level, most psychedelic substances remain classified as illegal under U.S. law. However, the legal landscape is changing at the state and local levels. Some states and cities have passed laws decriminalizing certain psychedelics or allowing their supervised medical use.
These policy shifts reflect growing public interest and changing attitudes, but they also create confusion. Legal protections vary widely by location, and federal law continues to apply in many situations. Individuals who choose to use psychedelics may face legal risks depending on where they live.
The fact that millions of Americans are microdosing psychedelics has significant implications for public health. On one hand, it suggests unmet needs in mental health care, particularly for conditions like anxiety and depression. On the other hand, it highlights the risks of widespread self experimentation without medical guidance.
Researchers emphasize the need for more high quality studies to understand the benefits, risks, and long term effects of microdosing. Better data could help inform public policy, medical guidelines, and harm reduction strategies.
Education is also critical. Many users may not fully understand the substances they are taking, especially when it comes to toxicity, interactions, and mental health risks. Clear, evidence based information could help reduce preventable harm.
The RAND study titled U.S. Psychedelic Use and Microdosing in 2025 offers one of the most comprehensive snapshots to date of how Americans are using psychedelics. It shows that microdosing is no longer a fringe behavior, but a mainstream practice among people who use these substances.
As research continues and laws evolve, the conversation around psychedelics is likely to become more nuanced. Policymakers, healthcare providers, and researchers will need to balance potential therapeutic benefits with safety concerns and ethical considerations.
For now, the findings serve as a reminder that psychedelic use in America is changing rapidly, often ahead of scientific consensus and regulatory frameworks.
RAND Corporation, news release, January 21, 2026
This article is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Statistical data reflects general trends and may not apply to individual circumstances. Psychedelic substances carry legal, medical, and psychological risks. Always consult a qualified healthcare professional before making decisions related to mental health or substance use.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.